Hepatitis C Virus

Albuferon-alpha well tolerated, has prolonged half-life

Published in Hepatitis Weekly, January 27th, 2003

Human Genome Sciences, Inc., (HGSI) presented the results of 3 phase I clinical trials of its new drugs to an audience of financial analysts and investors at the 21st Annual JP Morgan H&Q Healthcare Conference in San Francisco.

Results were reported for phase I clinical trials of Albuferon-alpha in adults with hepatitis C, and of BLyS in patients with common variable immunodeficiency (CVID). The company also discussed previously disclosed results of a phase I clinical trial of Albutropin in adults with growth hormone deficiency, and provided an update on the progress of other drugs in Human Genome Sciences' clinical development pipeline.

During its...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2003-01-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry